Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
The purpose of this study is to confirm the safety of Apatinib at a dose level up to 750 mg/d with standard therapy of docetaxel (60 mg/m²) in advanced lung adenocarcinoma patients harboring wild-type EGFR after failure of first line chemotherapy and to determine the recommended dose for the Phase II trial.
Lung Adenocarcinoma
DRUG: Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|DRUG: Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|DRUG: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
Maximum tolerated dose (MTD) of Apatinib in combination with Docetaxel (60 mg/m2), During the first treatment course, up to 3 weeks|Number of Participants Experienced Dose Limited Toxicity (DLT) in Combination Therapy of Apatinib and Docetaxel, During the first treatment course, up to 3 weeks
Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 for All Courses, Between the first administration of Docetaxel and 28 days after last administration of Apatinib, up to 1 year|Objective Response Rate (ORR), Every 6 weeks from the first treatment course, up to 1 year|Progression-free Survival (PFS), Every 6 weeks from the first treatment course, up to 2 year
The purpose of this study is to confirm the safety of Apatinib at a dose level up to 750 mg/d with standard therapy of docetaxel (60 mg/m²) in advanced lung adenocarcinoma patients harboring wild-type EGFR after failure of first line chemotherapy and to determine the recommended dose for the Phase II trial.